Trovagene leaps on urine-based cancer mutation test news

|By:, SA News Editor

Shares of Trovagene (TROV +16.6%) soar as the company announces the availability of the first urine test for cancer mutation monitoring.

The cell-free BRAF test detects and monitors V600E BRAF mutation, replacing tissue sample-based monitoring which "has limited practicality for patient monitoring due to costs, tumor heterogeneity and potential complications from the biopsy process." (PR)

Aegis' Raghuram Selvaraju says the news marks "a significant milestone for the company and [is] a core component of the firm's strategy aimed at attaining profitability near-term."